- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07574008
Danish Pulses Meal Study (Danish Pulses)
Danish Pulses: Tasty, Healthy, and Safe Danish Pulses With Added Value for The Users
The goal of this clinical trial is to learn whether daily intake of lactic acid bacteria fermented or unfermented legumes can improve metabolic and gut health in healthy adults.
The main questions it aims to answer are:
- Does eating 100 g per day of legumes for 2 weeks lower blood glucose, measured primarily by continuous glucose monitoring, compared with a control period of habitual diet?
- Does eating 100 g per day of legumes for 2 weeks improve inflammation, cholesterol, gut microbiome composition, and short-chain fatty acid (SCFA) levels, and do fermented legumes have additional effects on body composition compared with unfermented legumes? Researchers will compare participants consuming LAB-fermented legumes with participants consuming unfermented legumes to see if fermented legumes produce greater health benefits, particularly for body composition and other metabolic outcomes.
Participants will:
- Follow their habitual diet for 14 days during a control period.
- Complete baseline measurements after the control period.
- Be randomly assigned to consume 100 g per day of either LAB-fermented or unfermented legumes for 14 days.
- Eat the provided standardized legume foods as part of their usual meals.
- Undergo continuous glucose monitoring and other assessments, incl. inflammation, cholesterol, long-term blood glucose, blood pressure, body composition, fecal microbiome, dietary intake, and digestive symptoms.
연구 개요
상태
연구 유형
등록 (추정된)
단계
- 해당 없음
연락처 및 위치
연구 연락처
- 이름: Tenna Mie Christoffersen, ph.D
- 전화번호: +45 72482246
- 이메일: tch@pha.dk
연구 연락처 백업
- 이름: Louise Almer, phD student
- 전화번호: +45 72482258
- 이메일: loua@pha.dk
연구 장소
-
-
-
Slagelse, 덴마크, 4200
- University College Absalon
-
연락하다:
- Kim Daugaard
- 전화번호: +45 72 482229
- 이메일: kimd@pha.dk
-
연락하다:
- Martin Smedegaard Vinvig
- 전화번호: +45 72482261
- 이메일: mavi@pha.dk
-
수석 연구원:
- Tenna Christoffersen, PhD
-
부수사관:
- Louise Almer, PhD student
-
-
참여기준
자격 기준
공부할 수 있는 나이
- 성인
건강한 자원 봉사자를 받아들입니다
설명
Inclusion Criteria:
- No diabetes
Exclusion Criteria:
- Treatment with antibiotics within the last three months.
- Ongoing treatment with non-steroidal anti-inflammatory drugs.
- Metabolic diseases, including diabetes.
- Inflammatory bowel disease (IBD), such as Crohn's disease or ulcerative colitis.
- Allergies or intolerance to legumes.
- People that report eating > 25 g per day of legumes as part of their habitual diet.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 방지
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Fermented pulses group 1
Participants will be instructed to consume 100 g of lactic acid fermented pulses daily as part of their usual diet.
|
The participants are randomly assigned to two experimental groups based on a randomized trial design: two weeks of habitual dietary intake (control period) followed by the second intervention period lasts from day 14 to day 28, during which participants will be instructed to consume 100 g of lactic acid fermented pulses every day, seven days a week, for two weeks.
Fermented pulses will be provided and packed as standardized food items to their habitual meals e.g. as hummus, or pasta with legume flour, adding up to 100 g of legumes per day.
These test foods can be eaten throughout the day; however, intake of other legumes, except those included in the foods, should be avoided.
|
|
실험적: Unfermented pulses group 2
Participants will be instructed to consume 100 g of unfermented pulses daily as part of their usual diet.
|
The participants are randomly assigned to two experimental groups based on a randomized trial design: two weeks of habitual dietary intake (control period) followed by the second intervention period lasts from day 14 to day 28, during which participants will be instructed to consume 100 g of unfermented pulses every day, seven days a week, for two weeks.
The unfermented pulses will be provided and packed as standardized food items to their habitual meals e.g. as hummus, or pasta with legume flour, adding up to 100 g of legumes per day.
These test foods can be eaten throughout the day; however, intake of other legumes, except those included in the foods, should be avoided.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Continuous glucose monitoring
기간: From day zero to 14 days and from day 14 to day 28
|
Continuous Glucose Monitoring (CGM) will be measured in real-time and intermittently scanned CGM (isCGM) bi-weekly with an isCGM sensor (model Abbott Freestyle Libre PRO).
This method is a minimally invasive method, as the sensor is placed on the participant's arm (26-30), by participants themselves after careful instructions, incl.
videos.
The Abbott Freestyle Libre PRO is blinded to the participants to avoid habitual changes, and it measures CGM in real-time throughout the entire 14-day period.
The study follows the Standardized CGM metrics for Clinical Care, and the 14-day duration is aligned with the international recommendations (26,30).
To ensure accurate and meaningful interpretation of CGM, adequate glucose data is collected according to the recommendation (70% of data from 14 days) (26,30).
Data from participants with a CGM activity < 70% will be analyzed with the intention to treat principles.
|
From day zero to 14 days and from day 14 to day 28
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Inflammation CRP level
기간: Three measures; at baseline (day 0), follow up 1(day 14) and at follow up 2 (day 28).
|
Fasting C-reactive proteins (CRP) monitoring will be measured at baseline, 14 days, and at day 28 by a finger prick test using a QuickRead go PLUS Instrument (#154580-4).
|
Three measures; at baseline (day 0), follow up 1(day 14) and at follow up 2 (day 28).
|
|
Fasting Cholesterol
기간: Three measures; at baseline (day 0), follow up 1(day 14) and at follow up 2 (day 28).
|
Fasting cholesterol monitoring will be conducted at baseline, 14 days, and at day 28 by a finger prick test using a QuickRead go PLUS Instrument (#154580-4).
|
Three measures; at baseline (day 0), follow up 1(day 14) and at follow up 2 (day 28).
|
|
Long-term blood glucose
기간: Three measures; at baseline (day 0), follow up 1(day 14) and at follow up 2 (day 28).
|
Fasting hemoglobin A1c (HbA1c) monitoring will be conducted at baseline, 14 days, and at day 28 by a finger prick test using a QuickRead go PLUS Instrument (#154580-4).
|
Three measures; at baseline (day 0), follow up 1(day 14) and at follow up 2 (day 28).
|
|
Blood pressure
기간: Three measurements; at baseline (day 0), follow up 1 (day 14) and at follow up 2 (day 28).
|
Systolic and diastolic blood pressures will be measured at baseline, day 14, and at day 28.
Blood pressures will be measured in millimeters of mercury using an automatic blood pressure monitor (Digital Automatic Blood Pressure Monitor, Omron).
Participants will be asked to lie down and relax for approximately 8 to 10 minutes, and 3 blood pressure measurements will be recorded at 5-minute intervals.
|
Three measurements; at baseline (day 0), follow up 1 (day 14) and at follow up 2 (day 28).
|
|
Body composition
기간: Three measurements; at baseline (day 0), follow up 1 (day 14) and at follow up 2 (day 28).
|
Anthropometric measurements, will be measured by a Body Impedance Analytics (BIA) (TANITA MC 780 MA S, Japan). Height (m) will be measured using a standard dynamometer without shoes and is recorded to the nearest 0.1 cm. Body mass index (BMI) is calculated by dividing weight (kg) by height (m) squared (kg/m2). Waist and hip circumferences will be measured using a standardized tape measure that is calibrated before use. Waist circumference (cm) will be measured at the midpoint between the lowest rib and the upper part of the iliac bone in a standing position. Hip circumference (cm) will be measured at the site of the largest circumference between the waist and thighs. |
Three measurements; at baseline (day 0), follow up 1 (day 14) and at follow up 2 (day 28).
|
|
Fecal sample
기간: Three measurements: at baseline (day 0), follow up 1 (day 14), and at follow up 2 (day 28).
|
Fecal samples (approximately 10 g) will be collected from all participants.
Participants are collecting the samples by themselves using the EasySampler tool kit, including a thorough written introduction(33,34).
Fecal pH will be determined by mixing fecal matter 1:2 with sterile MilliQ-water after which pH is measured.
Total fecal DNA will be extracted using standard methods.
The gut microbial metagenome will be determined by shotgun high-throughput sequencing using long-read Oxford Nanopore-based sequencing.
Before any further bioinformatics processing the raw reads will be purged of any human DNA-related sequences.. Fecal short chain fatty acids and other fecal metabolite concentrations, incl.
free amino acids, are determined using high-field nuclear magnetic resonance NMR on fecal samples.
|
Three measurements: at baseline (day 0), follow up 1 (day 14), and at follow up 2 (day 28).
|
|
Dietary intake
기간: Three measurements: at baseline (day 0), follow-up 1 (day 14) and follow-ip 2 (day 28).
|
Data on dietary intake will be collected by three-day dietary records with photos to evaluate adherence to the intervention. The dietary records will be collected once during the control period and once during the intervention period. Photos will be used for main meals and leftovers of legumes. Physical activity will also be documented as part of the dietary records and used to estimate energy expenditure. Furthermore, data on dietary intake will be used to assess compliance with the intervention. |
Three measurements: at baseline (day 0), follow-up 1 (day 14) and follow-ip 2 (day 28).
|
|
Digestive abnormalities
기간: Three measurements: at baseline (day 0) , follow-up 1 (day 14), and at follow-up 2 (day 28).
|
Digestive abnormalities are identified through IBS symptoms and will be assessed using self-reported questionnaires using the IBS Severity Scoring System (IBS-SSS) for assessment of the following symptoms: abdominal distension, abdominal pain, satisfaction with bowel habits, and the extent to which symptoms affect the quality of life (QoL).
|
Three measurements: at baseline (day 0) , follow-up 1 (day 14), and at follow-up 2 (day 28).
|
공동 작업자 및 조사자
수사관
- 연구 책임자: Margit Dall Aaslyng, PhD, University College Absalon
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- SJ-1132-120770
- 34009-23-2191 (기타 보조금/기금 번호: Green Development and Demonstration Programme (GUDP))
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
Pulses meal study에 대한 임상 시험
-
Helse-Bergen HFUniversity Hospital of North Norway; Helse Forde완전한발달성 고관절 이형성증
-
Fonds de la Recherche en Santé du QuébecUniversité de Montréal완전한
-
Radicle Science완전한
-
Hospital Clinic of BarcelonaUniversitat Politècnica de Catalunya; Institut Catala de Salut; Department of Health, Generalitat... 그리고 다른 협력자들알려지지 않은